- p. 828.210.9300
- f. 828.210.9319
These studies are currently available at Asheville Neurology Specialists for patients who qualify for participation. If you are interested in learning more about these studies or clinical trials, please contact Susan Woodard, CCRC at email@example.com or 828-210-9311.
Biogen– Tysabri vs. placebo for 6 months of double blind followed by 6 months of open label Tysabri. Criteria: for patients with 4 or more seizures per month.
Xenon: 12 week double blind study with new seizure medication, followed by open label extension with new drug. Criteria: for patients with 4 or more seizures per month.
Novartis – open label Siponimod for MS patients who are transitioning to a new agent, 6 months of open label medication provided
Pharma Two B – 12 week study of study drug vs. Mirapex vs. Azilect for early/new onset of PD. Criteria: no previous exposure to PD treatment (or less than 4 weeks, > 2 months prior to study entry).